Saturday 17 October 2026
Export NRXS’s income statement to Excel — free account
Neuraxis, Inc.
NRXS Healthcare Biotechnology
Neuraxis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.6 million, up 32.9% from fiscal 2024. In the quarter to June 2026, revenue grew 115.7%, EPS grew 13.6% and free cash flow grew 29.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
7.70
0.04
−0.52%
Follow NRXS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 4 | 4 | 5 |
| (3,433.40%) | (315.62%) | (269.21%) | (153.96%) | ||
| (240.65%) | (154.37%) | (137.13%) | (98.96%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(432.27%) | (285.58%) | (149.62%) | (132.43%) | |
Average Days of Receivables |
11.78 | 20.01 | 32.82 | 29.72 | |
Free Cash Flow per Share |
(0.64) | (0.73) | (0.55) | (0.47) | |
Free Cash Flow |
(6.28) | (6.60) | (6.06) | (5.64) | |
Capital Expenditures |
(0.03) | (0.17) | — | (0.02) | |
| Other line items | |||||
Cash ROIC |
(94.30%) | (78.96%) | (47.24%) | (37.46%) | |
Accounts Receivable Turnover |
41.74 | 16.21 | 13.62 | 18.94 | |
Accounts Payable Turnover |
0.58 | 1.53 | 1.53 | 1.22 | |
Inventory Turnover |
8.10 | 3.74 | 4.66 | 3.76 | |
Average Days of Payables |
601.37 | 90.39 | 173.63 | 376.31 | |
Days of Inventory on Hand |
74.83 | 166.71 | 135.52 | 131.82 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
18.19% | 13.83% | 11.10% | 11.94% | |
Selling, General and Administrative Expense of Revenue |
291.24% | 289.77% | 243.84% | 218.14% | |
Share Based Compensation of Revenue |
13.08% | 16.72% | 19.16% | 24.21% | |
Interest Coverage |
(97.30) | (75.22) | (56.80) | (57.12) | |
Operating CF/Net income |
0.75 | 0.75 | 0.75 | 0.67 | |
Depreciation/Fixed assets |
0.49 | 0.79 | 1.03 | 1.12 | |
Capex/Depreciation |
(0.60) | (2.89) | 0.00 | (0.27) | |
Revenue per Share |
0.34 | 0.39 | 0.39 | 0.44 | |
Operating CF per Share |
(0.63) | (0.71) | (0.55) | (0.46) | |
Capex per Share |
0.00 | (0.02) | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.05 | 0.00 | 0.00 |
Columns are period end dates